In conclusion, our study provides new insight into a mechanism of osimertinib resistance attributable to TP53-GOF mutations and suggests that TNF-α inhibition might be an effective strategy to overcome osimertinib resistance in patients with EGFR mutation-positive NSCLC with coexisting TP53-GOF mutations. This evidence concerns the gene TNF and non-small cell lung carcinoma.